NCT03395899 - Pre-operative Immunotherapy Combination Strategies in Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

August 18, 2023

Study Completion Date

August 18, 2023

Conditions

Breast CancerEstrogen Receptor-positive Breast Cancer

Interventions

DRUG

Atezolizumab

PD-L1 antibody

DRUG

Cobimetinib

Highly selective small-molecule inhibitor of MEK1 and MEK2

DRUG

Ipatasertib

Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt

DRUG

Bevacizumab

Highly specific humanized monoclonal antibody that targets VEGF

Trial Locations (1)

Barts Health NHS Trust, London